Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure

Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17.


Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin receptor activator, is the longest acting erythropoiesis-stimulating agent currently available. MPG-EPO is characterized by an elimination half-life of approximately 137 h and offers extended dosing intervals up to 4 weeks. Numerous phase I/II studies and a comprehensive clinical phase III program demonstrated the feasibility of MPG-EPO therapy for anemia correction and maintenance of stable hemoglobin levels in adult chronic kidney disease patients. Due to patent disputes MPG-EPO was only available outside the US market so far. In view of a prevailing US market introduction, this review focuses on efficacy and safety data from pivotal trials, summarizes recent clinical research and finally tries to substantiate potential benefits associated with the use of this anti-anemic drug.

Keywords: Anemia; C.E.R.A.; CKD; ESRD; Mircera; epoetin; erythropoiesis-stimulating agents; methoxy polyethylene glycol-epoetin beta.

Publication types

  • Review

MeSH terms

  • Anemia / complications*
  • Anemia / drug therapy
  • Erythropoietin / adverse effects*
  • Humans
  • Kidney Failure, Chronic / drug therapy
  • Kidney Failure, Chronic / etiology*
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins / adverse effects


  • Recombinant Proteins
  • continuous erythropoietin receptor activator
  • epoetin beta
  • Erythropoietin
  • Polyethylene Glycols